ReviewCytokine & growth factor reviews2021
Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19.
Review in Cytokine & growth factor reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interferon-induced transmembrane protein 3 gene polymorphisms are associated with COVID-19 susceptibility and severity: A meta-analysis.The Journal of infection · 2022Pooled it
- Mapping Interactions Between Cytokines, Chemokines, Growth Factors, and Conventional Biomarkers in COVID-19 ICU-Patients.International journal of molecular sciences · 2025Article
- Immune Cell-Based versus Albumin-Based Ratios as Outcome Predictors in Critically Ill COVID-19 Patients.Journal of inflammation research · 2025Article
- Immunomodulatory effect of bovine lactoferrin during SARS-CoV-2 infection.Frontiers in immunology · 2024Article
- sTREM-1 as a Predictive Biomarker for Disease Severity and Prognosis in COVID-19 Patients.Journal of inflammation research · 2024Article
- Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024Review
- Post-hospitalization rehabilitation alleviates long-term immune repertoire alteration in COVID-19 convalescent patients.Cell proliferation · 2023Article
- Neutrophils in COVID-19: recent insights and advances.Virology journal · 2023Review
- Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality.Scientific reports · 2022Article
- Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes.Frontiers in immunology · 2022Article
- Extracorporeal Membrane Oxygenation for Secondary Organizing Pneumonia after Severe SARS-CoV-2 Infection: A Case Report.Medicina (Kaunas, Lithuania) · 2021Article
- SARS-CoV-2-related IFITM3 in immune dysfunction and tumor microenvironment: An integrative analysis in pan-cancers.Clinical and translational medicine · 2021Article
- Potential Immune Indicators for Predicting the Prognosis of COVID-19 and Trauma: Similarities and Disparities.Frontiers in immunology · 2021Review
- A Model Predicting Mortality of Hospitalized Covid-19 Patients Four Days After Admission: Development, Internal and Temporal-External Validation.Frontiers in cellular and infection microbiology · 2021Article
- Identifying New COVID-19 Receptor Neuropilin-1 in Severe Alzheimer's Disease Patients Group Brain Using Genome-Wide Association Study Approach.Frontiers in genetics · 2021Article
- Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms.Journal of translational autoimmunity · 2021Article
- Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), appears with a wide spectrum of mild-to-critical clinical complications. Many clinical and experimental findings suggest the role of inflammatory mechanisms in the immunopathology of COVID-19. Hence, cellular and molecular mediators of the immune system can be potential targets for predicting, monitoring, and treating the progressive complications of COVID-19. In this review, we assess the latest cellular and molecular data on the immunopathology of COVID-19 according to the pathological evidence (e.g., mucus and surfactants), dysregulations of pro- and anti-inflammatory mediators (e.g., cytokines and chemokines), and impairments of innate and acquired immune system functions (e.g., mononuclear cells, neutrophils and antibodies). Furthermore, we determine the significance of immune biomarkers for predicting, monitoring, and treating the progressive complications of COVID-19. We also discuss the clinical importance of recent immune biomarkers in COVID-19, and at the end of each section, recent clinical trials in immune biomarkers for COVID-19 are mentioned.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.